{"id":"eicosapentaenoic-acid-ethyl-ester","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Bleeding or bruising"},{"rate":null,"effect":"Fishy aftertaste"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"EPA ethyl ester is a purified form of eicosapentaenoic acid (EPA), an omega-3 fatty acid that acts as a substrate for anti-inflammatory mediators and reduces hepatic triglyceride synthesis. It lowers circulating triglycerides and may improve endothelial function and reduce cardiovascular inflammation through multiple lipid and inflammatory pathways.","oneSentence":"Eicosapentaenoic acid ethyl ester is an omega-3 polyunsaturated fatty acid that reduces triglyceride levels and modulates lipid metabolism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:36:13.950Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertriglyceridemia"},{"name":"Cardiovascular disease prevention"}]},"trialDetails":[{"nctId":"NCT06466278","phase":"PHASE2","title":"IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-06-01","conditions":"Aortic Valve Stenosis","enrollment":110},{"nctId":"NCT05198843","phase":"PHASE1, PHASE2","title":"Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-08","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma","enrollment":1},{"nctId":"NCT04152291","phase":"NA","title":"The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism","status":"COMPLETED","sponsor":"Wihuri Research Institute","startDate":"2019-11-12","conditions":"Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility, Low-density Lipoprotein Lipid Composition","enrollment":68},{"nctId":"NCT03428477","phase":"PHASE3","title":"EPA for Metastasis Trial 2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mark A Hull, PhD FRCP","startDate":"2018-05-02","conditions":"Liver Metastasis, Colon Cancer","enrollment":418},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":"Coronary Artery Disease, Atherosclerosis, Heart Attack","enrollment":""},{"nctId":"NCT06758778","phase":"NA","title":"CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting Conditions","status":"ENROLLING_BY_INVITATION","sponsor":"Sichuan Credit Pharmaceutical Co., Ltd.","startDate":"2025-01-03","conditions":"Bioavailability","enrollment":14},{"nctId":"NCT06720662","phase":"NA","title":"Effect of Icosapent-ethyl Ester (IPE) to Reduce the Residual Risk Cardiovascular Disease.","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2025-04-01","conditions":"Atherosclerosis Cardiovascular Disease","enrollment":294},{"nctId":"NCT06710080","phase":"PHASE3","title":"Targeting Vascular INflammation in Patients with Community-Acquired Pneumonia","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2024-12-15","conditions":"Inflammation, Community Acquired Pneumonia (CAP), Inflammation Plaque, Atherosclerotic","enrollment":168},{"nctId":"NCT04682665","phase":"","title":"Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2021-09-16","conditions":"Colon Cancer Liver Metastasis","enrollment":81},{"nctId":"NCT02719327","phase":"PHASE2, PHASE3","title":"Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2017-06-08","conditions":"Alzheimer's Disease","enrollment":131},{"nctId":"NCT04239950","phase":"PHASE3","title":"Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2020-05-09","conditions":"Hypertriglyceridemia","enrollment":316},{"nctId":"NCT04216251","phase":"PHASE1, PHASE2","title":"PRevention Using EPA Against coloREctal Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-12-09","conditions":"Colorectal Adenoma, Colorectal Cancer, Endoscopic Surgery","enrollment":81},{"nctId":"NCT04562467","phase":"PHASE4","title":"The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk","status":"COMPLETED","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2020-09-24","conditions":"Cardiovascular Diseases, Cardiovascular Risk Factor, Triglycerides High","enrollment":70},{"nctId":"NCT04268134","phase":"PHASE2","title":"Altering Lipids for Tolerance of Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-07-28","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT05491759","phase":"PHASE4","title":"A Study to Determine Optimal Absorption of Single Dose Omega-3","status":"COMPLETED","sponsor":"RDC Clinical Pty Ltd","startDate":"2022-08-04","conditions":"Optimal Gastrointestinal Absorption of Omega-3","enrollment":22},{"nctId":"NCT04505098","phase":"PHASE4","title":"A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults","status":"TERMINATED","sponsor":"Kaiser Permanente","startDate":"2020-08-07","conditions":"Covid19, Atherosclerosis, Cardiovascular Diseases","enrollment":39600},{"nctId":"NCT04198805","phase":"PHASE2","title":"Vitamin E and DHA-EE on NAFLD - Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial (PUVENAFLD)","status":"COMPLETED","sponsor":"Naga P. Chalasani","startDate":"2020-01-03","conditions":"Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Fatty Liver, Non-Alcoholic Steatohepatitis","enrollment":205},{"nctId":"NCT05271591","phase":"","title":"Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Disease in Canada (REDUCE-IT Canada SA)","status":"COMPLETED","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2022-03-05","conditions":"Cardiovascular Diseases, Atherosclerotic Cardiovascular Disease, Myocardial Infarction","enrollment":200},{"nctId":"NCT03443076","phase":"NA","title":"Bioavailability of EPA + DHA in a SMEDS Formulation","status":"COMPLETED","sponsor":"Midwest Center for Metabolic and Cardiovascular Research","startDate":"2018-02-16","conditions":"Bioavailability","enrollment":24},{"nctId":"NCT02926027","phase":"PHASE4","title":"Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy","status":"COMPLETED","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-03-28","conditions":"Hypertriglyceridemia","enrollment":80},{"nctId":"NCT00915902","phase":"PHASE2, PHASE3","title":"Fish Oil Study for High Triglyceride Levels in Children","status":"COMPLETED","sponsor":"Babu Balagopal","startDate":"2009-07","conditions":"Hypertriglyceridemia","enrollment":42},{"nctId":"NCT04811404","phase":"PHASE4","title":"A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2021-03-19","conditions":"Bipolar Disorder","enrollment":""},{"nctId":"NCT02113163","phase":"PHASE1","title":"PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA","status":"COMPLETED","sponsor":"Thetis Pharmaceuticals LLC","startDate":"2014-03","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia","enrollment":32},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT02422446","phase":"PHASE3","title":"Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2015-04","conditions":"Type 2 Diabetes, Coronary Artery Disease","enrollment":2},{"nctId":"NCT02781584","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-06-13","conditions":"Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)","enrollment":220},{"nctId":"NCT04177680","phase":"PHASE2","title":"Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2020-06-03","conditions":"Hypertriglyceridemia","enrollment":100},{"nctId":"NCT02101970","phase":"NA","title":"Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women","status":"COMPLETED","sponsor":"Carol Fabian, MD","startDate":"2014-03","conditions":"Breast Cancer","enrollment":46},{"nctId":"NCT04412018","phase":"PHASE2","title":"An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19","status":"COMPLETED","sponsor":"Canadian Medical and Surgical Knowledge Translation Research Group","startDate":"2020-06-04","conditions":"COVID-19, Inflammatory Response","enrollment":100},{"nctId":"NCT03661047","phase":"PHASE2","title":"OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-11-30","conditions":"Colon Cancer","enrollment":""},{"nctId":"NCT03885661","phase":"PHASE1","title":"Vascepa to Accelerate Lipoprotein Uptake and Elimination","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-01-11","conditions":"Lipid Disorder, Triglycerides High, Dyslipidemias","enrollment":20},{"nctId":"NCT04460651","phase":"PHASE3","title":"PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial","status":"COMPLETED","sponsor":"Estudios Clínicos Latino América","startDate":"2020-08-14","conditions":"COVID19","enrollment":4093},{"nctId":"NCT02940223","phase":"PHASE2","title":"Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-03-16","conditions":"Advanced Malignant Neoplasm, Fatigue","enrollment":2},{"nctId":"NCT04159532","phase":"PHASE4","title":"Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)","status":"COMPLETED","sponsor":"SCF Pharma","startDate":"2019-12-18","conditions":"Healthy Adults","enrollment":36},{"nctId":"NCT04761952","phase":"NA","title":"N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease","status":"UNKNOWN","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2021-02-13","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Polyunsaturated Acid Lipidosis","enrollment":236},{"nctId":"NCT02708771","phase":"PHASE3","title":"Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity","status":"COMPLETED","sponsor":"Hospital San Juan de la Cruz","startDate":"2016-03","conditions":"Heart Failure","enrollment":42},{"nctId":"NCT01041521","phase":"PHASE4","title":"The Impact of Omega Three Fatty Acids on Vascular Function in HIV","status":"COMPLETED","sponsor":"Tufts University","startDate":"2010-01","conditions":"High Triglyceride Level, HIV Infection","enrollment":129},{"nctId":"NCT00795717","phase":"PHASE4","title":"Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial","status":"COMPLETED","sponsor":"Tufts University","startDate":"2008-07","conditions":"Cardiovascular Disease, HIV Infection","enrollment":41},{"nctId":"NCT03693131","phase":"PHASE3","title":"Efficacy of MND-2119 in Participants With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2018-10-27","conditions":"Hypertriglyceridemia","enrollment":580},{"nctId":"NCT03072823","phase":"NA","title":"Omega-3 Polyunsaturated Fatty Acids on Major Depressive Disorder in Patients With Cardiovascular Diseases","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2016-01-27","conditions":"Cardiovascular Diseases, Major Depressive Disorder","enrollment":60},{"nctId":"NCT02148835","phase":"NA","title":"Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals","status":"COMPLETED","sponsor":"Clemens von Schacky","startDate":"2014-05","conditions":"Healthy Volunteers","enrollment":44},{"nctId":"NCT03542643","phase":"NA","title":"Omega-3 Polyunsaturated Fatty Acids in Youth With ADHD","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2016-07-07","conditions":"Attention Deficit Hyperactivity Disorder, ADHD","enrollment":105},{"nctId":"NCT00504309","phase":"NA","title":"Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides","status":"COMPLETED","sponsor":"Penn State University","startDate":"2007-07","conditions":"Hypertriglyceridemia","enrollment":28},{"nctId":"NCT00815685","phase":"NA","title":"A Pilot Study of Eicosapentaenoic Acid (EPA) in Patients With Cancer Cachexia","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2007-07","conditions":"Cancer Cachexia","enrollment":36},{"nctId":"NCT00828178","phase":"PHASE4","title":"Efficacy of Fish Oil in Lupus Patients","status":"COMPLETED","sponsor":"Michelle Petri M.D.,MPH","startDate":"2009-02","conditions":"Systemic Lupus Erythematosus","enrollment":106},{"nctId":"NCT01350973","phase":"PHASE3","title":"Efficacy of TAK-085 in Participants With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11","conditions":"Hypertriglyceridemia","enrollment":611},{"nctId":"NCT01350999","phase":"PHASE3","title":"Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11","conditions":"Hypertriglyceridemia","enrollment":503},{"nctId":"NCT02859129","phase":"PHASE1","title":"Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2013-09","conditions":"Hypertriglyceridemia","enrollment":114},{"nctId":"NCT02865044","phase":"NA","title":"Study to Evaluate the Acute Bioavailability of EPA and DHA From a DietarySupplement in Healthy Men and Women","status":"COMPLETED","sponsor":"Calanus","startDate":"2015-03","conditions":"Healthy","enrollment":18},{"nctId":"NCT00944229","phase":"PHASE3","title":"The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure","status":"TERMINATED","sponsor":"Columbia University","startDate":"2010-01","conditions":"Heart Failure","enrollment":58},{"nctId":"NCT01960660","phase":"NA","title":"A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products","status":"COMPLETED","sponsor":"Nordic Pharma, USA","startDate":"2012-05","conditions":"Comparative Bioavailability","enrollment":35},{"nctId":"NCT00231738","phase":"PHASE4","title":"Protective Effect of EPA on Cardiovascular Events","status":"COMPLETED","sponsor":"Kobe University","startDate":"1996-11","conditions":"Myocardial Infarction, Unstable Angina Pectoris, Sudden Cardiac Death, Stroke, Peripheral Artery Disease","enrollment":18000},{"nctId":"NCT01208961","phase":"PHASE2","title":"Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-09","conditions":"Severe Hypertriglyceridemia","enrollment":54},{"nctId":"NCT01431690","phase":"PHASE1","title":"Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-08","conditions":"Hypertriglyceridemia","enrollment":52},{"nctId":"NCT01817400","phase":"EARLY_PHASE1","title":"Mediators of Abnormal Reproductive Function in Obesity (MARO)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2013-03","conditions":"Infertility, Female, Obesity","enrollment":10},{"nctId":"NCT01154985","phase":"PHASE2","title":"Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)","status":"COMPLETED","sponsor":"Mochida Pharmaceutical Company, Ltd.","startDate":"2010-06","conditions":"Steatohepatitis","enrollment":243},{"nctId":"NCT00634361","phase":"PHASE2, PHASE3","title":"Ethyl-EPA Treatment of Prodromal Patients","status":"COMPLETED","sponsor":"Yale University","startDate":"2001-09","conditions":"Schizophrenia Prodrome","enrollment":7},{"nctId":"NCT00069784","phase":"PHASE3","title":"The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-08","conditions":"Diabetes Mellitus, Non-Insulin-Dependent","enrollment":12537},{"nctId":"NCT01369550","phase":"NA","title":"Efficacy Study of Stearidonic Acid (SDA) Soybean Oil-containing Foods on Red Blood Cell Fatty Acid Content","status":"COMPLETED","sponsor":"Monsanto Company, LLC","startDate":"2010-08","conditions":"Healthy Volunteers, Markers of Cardiovascular Risk","enrollment":127},{"nctId":"NCT01216982","phase":"PHASE2","title":"Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders","status":"UNKNOWN","sponsor":"United States Department of Defense","startDate":"2010-11","conditions":"Mood Disorders, Depression, Combat Disorders","enrollment":256},{"nctId":"NCT00419146","phase":"PHASE2, PHASE3","title":"Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants","status":"COMPLETED","sponsor":"University Hospital, Aker","startDate":"2001-09","conditions":"Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder","enrollment":99},{"nctId":"NCT00839449","phase":"PHASE4","title":"Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study","status":"COMPLETED","sponsor":"Yamaguchi University Hospital","startDate":"2004-12","conditions":"Subarachnoid Hemorrhage, Cerebral Vasospasm","enrollment":200},{"nctId":"NCT00692718","phase":"PHASE4","title":"N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure","status":"UNKNOWN","sponsor":"Osaka General Medical Center","startDate":"2008-07","conditions":"Acute Heart Failure, Acute Myocardial Infarction","enrollment":160},{"nctId":"NCT00001146","phase":"PHASE2","title":"Omega-3 Fatty Acids in the Treatment of Bipolar Disorder: A Double-Blind, Placebo-Controlled Trial","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1999-10","conditions":"Bipolar Disorder, Involutional Depression, Mood Disorder","enrollment":240},{"nctId":"NCT00096798","phase":"PHASE3","title":"Ethyl Eicosapentanoic Acid (Ethyl-EPA) for Treating Major Depression","status":"COMPLETED","sponsor":"National Center for Complementary and Integrative Health (NCCIH)","startDate":"2001-09","conditions":"Depressive Disorder, Depression","enrollment":80},{"nctId":"NCT00146211","phase":"PHASE3","title":"TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease","status":"COMPLETED","sponsor":"Amarin Neuroscience Ltd","startDate":"2005-09","conditions":"Huntington Disease","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":28,"reaction":"DRUG INEFFECTIVE"},{"count":20,"reaction":"MYOCARDIAL INFARCTION"},{"count":18,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":8,"reaction":"CEREBRAL INFARCTION"},{"count":6,"reaction":"ANGINA PECTORIS"},{"count":5,"reaction":"ACUTE GRAFT VERSUS HOST DISEASE"},{"count":5,"reaction":"ANGINA UNSTABLE"},{"count":5,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":4,"reaction":"ERYTHEMA"},{"count":4,"reaction":"ERYTHEMA MULTIFORME"}],"_approvalHistory":[],"publicationCount":106,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["EPADEL S900 TM (EPA ethyl ester, purity >98%)"],"phase":"marketed","status":"active","brandName":"Eicosapentaenoic acid ethyl ester","genericName":"Eicosapentaenoic acid ethyl ester","companyName":"Yamaguchi University Hospital","companyId":"yamaguchi-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eicosapentaenoic acid ethyl ester is an omega-3 polyunsaturated fatty acid that reduces triglyceride levels and modulates lipid metabolism. Used for Hypertriglyceridemia, Cardiovascular disease prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}